 |
| Author | Post |
|---|
Meg Mangin R.N.
Former Team Member
|
Posted: Wed Nov 22nd, 2006 03:01 |
|
 History of the Marshall Protocol
The Marshall Protocol was developed by Trevor Marshall, PhD, to treat sarcoidosis, from which he suffered.
"I had been playing with the light sensitivity issue since I spent a year on the equator, in 1974, teaching in Papua New Guinea. In 1986 I was standing on the central square of Stockholm's old town waiting for a walking-tour guide one day, and feeling progressively worse, when it suddenly hit me that the light sensitivity was way different from how medicine pictured it. Here I was in one of the most northern capitals of the world and there was little difference in the effect of the sun on me than when I was at the equator. At that time I figured that the light hypersensitivity must be 10 times or more, and not just a latitude thing.
It took me another 14 years behind really dark glasses (in semi-darkness) before the next breakthrough (Angiotensin II), and another two years to finally have the "eureka moment" (the VDR being key to innate immunity) where it all came together and made sense..."
If I remember, the Nilsson paper came out March 2002 http://tinyurl.com/jz2dy
I had previously decided, based on the biochemistry, that intra-cellular bacteria was the only thing which could produce run-away Th1 disease.
I had already discovered the photosensitivity back in 1986, so that was no longer a surprise.
When I saw the Nilsson photograph of the Rickettsia inside a macrophage that was a "eureka moment."
We had been looking into how we might treat these (obviously antibiotic resistant) bacteria when I came across a presentation by Joe Mercola (who was more mainstream back then) talking about his version of the AP - pulsed minocycline.
Benicar was just out by then, I think I changed to it in May or June 2002, as the ARBs I had been using since 1999 were no longer working for me.
By July of 2002 we had decided that pulsed minocycline was probably the best way to go, and several of us started out on this (longer than we expected) journey.
When the herxheimer hit we did understand what it was. And we took it as confirmation that we were on the correct path.
At the end of the first week, when a family outing to Disneyland made me realize my decade-old sun-sensitivity had dropped, I knew we had hit gold
As Louis Pasteur said "in science, chance favors the prepared mind"
Trevor Marshall, PhD
..............................................
From his research (spanning two decades), Dr. Marshall has found the protocol to have broad applications to a wide spectrum of chronic Th1 illnesses. He touches on the points of his education and career most relevant to his current work and explains the Marshall Protocol in more detail at:
Dr. Marshall's Interview at ImmuneSupport.com 07-06-04
This online community, MarshallProtocol. info, was created in July 2004 by Dr. Marshall and his research team to explain the protocol and to provide guidance and support to those who implement it.
Mar08
Back in 1978 I wrote a paper "Electronic Design Educating for an Uncertain Future" where I was wrote about "tackling .. tasks where the starting data may be vague, or incomplete, and where many alternative solutions may be equally valid."
The Idiopathic diseases present us with a very similar set of disparate and incomplete data. We can detect parasitic genomes, in-vitro, but have little data about whether they are active in-vivo, or what their effects might be, in-vivo. Additionally, there are tantalizing hints that other parasitic entities might be present, even though we can't detect them.
The Wirostko TEM micrographs, for example, showed a microbiota totally unknown to Medicine, yet clearly present in the patients Emil and his group were studying. Similarly, there had been many, many studies linking various known pathogens to Sarcoidosis, and CFS, yet none of them were clearly causal, as none of them were present in every individual.
The CFS patients in Australia, for example, who, if seropositive, were usually so for Rickettsia, suffer identically to those in the USA, who are often seropositive for Borrelia. Clearly neither of these pathogens were causal, and there were factors in play which were unknown, interacting in ways which were poorly understood.
That is why I took a different approach back in 1999. Building on my experience dealing with uncertain data and outcomes, I decided that in-vitro testing, the Gold-Standard of Medicine, just had to be missing something important. Similarly, the animal models were not producing results which were portable to human experience, so they, too, had to be set aside.
Thus, having discarded a century of studies, a century of what was thought to be "knowledge," I started to re-examine chronic disease based on the tools and techniques which had been developed for modern genetic biology. Trying to piece together the clues from a tiny subset of available perceptions and data, into a model which would be rigorous, and which would exactly describe the human experience. By its very nature, this study dealt largely with the philosophical. Only in later years did the science fall together into the rigorous mechanistic model we now have elucidated.
It is meaningless to focus on a virus, fungus, or bacterium which can be easily observed. Otherwise the pathogenesis of chronic disease would have been described decades ago. Being able to culture pathogen, or detect it with PCR, gives no clue as to whether that pathogen is causal in the disease process, or just present as a result of the immune system being weakened by an underlying disease process.
I know how tempting it is to apply the lab techniques of yesteryear to the imponderable problems of today. But one needs to start thinking, instead of focusing on observations. The fundamental problem with observational science is that unless you know what you are looking for, you don't know how, or why, to observe it. What is needed in modern medicine is the discipline of Planck and Einstein, the discipline of working with dilemma which defy description, and puzzle out, by sheer philosophical discipline, what the inter-relationships might be, in order that the data can then be experimentally observed, ranked, and the model verified.
..Trevor..
See also:
Interview with Belinda Fenter
Last edited on Mon Mar 24th, 2008 00:02 by Meg Mangin R.N.
____________________
Nothing contained in this site is or should be considered, or used as a substitute for, medical advice, diagnosis or treatment by your physician.
|
Meg Mangin R.N.
Former Team Member
|
Posted: Wed Nov 22nd, 2006 03:05 |
|
(filelink)
Dr Marshall's Profile
Job title
Adjunct Professor
Affiliations
School of Biological Sciences, Murdoch University, West Australia; Autoimmunity Research Foundation, California
Interests
Pathogenesis of chronic disease, and development of effective therapies for chronic disease.
Projects
Explore the activation of the Type 1 Nuclear Receptors, especially the VDR, using the modeling tools of molecular biology to explore ligand interactions, both endogenous and exogenous.
Explore the prokaryotic genomes present in the intraphagocytic microbiota which block the action of the VDR, and thus drive the pathology leading
Publications
See Papers for Physicians
Further information
Dr. Marshall's credentials
For the record and in the interests of accuracy, I want to clarify some things about the credentials of Trevor Marshall, Ph.D., as some have been speculating on them. I think there is some confusion because he did switch fields when he became ill with sarcoidosis and went from Engineering to Biomedical Engineering, though it may still have been under the School of Engineering. I suppose one could call it a multidisciplinary field, or in any case, he used his engineering background in the service of biomedical research. He first did research with a group of diabetes researchers at the University of Western Australia, and eventually had work published in the fields of diabetes and infertility.
One can see that he has at least 4 articles in PubMed, where peer-reviewed biomedical research is indexed (for the PubMed ones, see the ones with a PMID number, references # 2, 6, 7 and 8, at http://trevormarshall.com/papers.htm). On this site one can find the links directly to the PubMed listings. Eventually PubMed may index some of the older ones. He also has quite a few engineering publications and articles related to the Internet and computers.
It is true, as some have said, that a number of his initial research papers on sarcoidosis have been published in non-peer-reviewed journals such as clinmed and JOIMR, but his work has broken through that barrier in that he now has five papers published in medical print journals with a PubMed listed article on sarcoidosis research in Autoimmunity Reviews. And he was selected to participate in a collection of works on sarcoidosis by a Russian scientific publisher.
Dr. Marshall has also given presentations on Th1 inflammation and molecular modeling to physicians, researchers and scientists around the world. For a list of these papers and presentations (many available on DVD), See Papers and Presentations for Physicians
Joyce Waterhouse, Ph.D.
____________________
Nothing contained in this site is or should be considered, or used as a substitute for, medical advice, diagnosis or treatment by your physician.
|
Meg Mangin R.N.
Former Team Member
|
Posted: Wed Nov 22nd, 2006 03:17 |
|
(filelink)
A brief biography of Dr. Trevor Marshall, Ph.D.
Trevor Marshall graduated in electrical engineering from the University of Adelaide, South Australia, in 1973. He spent a year as tutor at the University of Technology in Lae, Papua, New Guinea, and in 1975, took a post lecturing at Curtin University, in Western Australia.
By 1978, Marshall had transitioned to microcomputers, and he gained his master’s degree, by thesis, in 1978. Moving to the University of Western Australia, he began work on his Ph.D. thesis in biomedicine, with clinical research at the Sir Charles Gairdner Hospital. Success using Pulsatile Lutenizing Hormone Releasing Hormone (LHRH) to treat cryptorchidism, and both male and female infertility, led to many publications and conference presentations during that early phase of his biomedical career.
In 1982, Marshall moved to California, simultaneously beginning a collaboration with the Hospital for Sick Children, in Toronto, which led to his Ph.D. thesis in 1984 on "Modelling and simulation in diabetes care." While Marshall was studying diabetes, cryptorchidism, and infertility during the early 1980s, it became apparent to him that patients with chronic diseases had several traits in common - particularly excessive fatigue and general neurological malaise. He wondered what else these diseases might share in common.
Through the decade of the 90's, Marshall achieved acclaim as a pioneer in the design of high-powered multiprocessing computers, some of which were used in the early PET scanners. He was at the forefront of the evolution of Internet and Linux technologies and he even had the experience of heading a technology company.
At the turn of the millennium, Marshall returned to his biomedical roots, focusing on the biochemistry associated with sarcoidosis and searching for the cause of the disease. He wondered what could cause a granulomatous disease like sarcoidosis to smolder and worsen and he knew that the only key to an effective treatment would be knowledge of the disease pathogenesis.
Marshall became especially intrigued by an observation that patients with sarcoidosis sometimes reacted to administration of Angiotensin Receptor Blockers (ARBs) with a neurologic reaction, including intense, vivid dreams. As a result, he was determined to find what this anomalous reaction might reveal about the disease process. Applying his knowledge of pharmacokinetics to the ARB dosing, he discovered that with higher dosing, the neurologic reactions ceased and the beneficial effects, including a noticeable reduction of some disease symptoms, became apparent.
Marshall’s evolving understanding of the disease unfolded, first and foremost, because he was trained as a scientist. By his very nature, he is acutely observant and he incessantly sought possible causes for every effect he observed. Almost incidentally, he also happened to suffer from sarcoidosis. Most people in this situation might have had their scientific ability clouded by bias from close personal knowledge of the disease, but Marshall had several things favoring him: his strong discipline, his intense drive to seek scientific truths, a memory that astonishes most of his colleagues and a spouse who was also trained in pharmacology. His wife, Liz, had her own research published even before they were married.
There was also a fortuitous development sometime after the millennium: the maturation of the Internet meant that medical publications were increasingly indexed and becoming available online. To someone like Marshall who was skilled at using this technology, that meant he could much more readily research obscure medical topics online and have access to journal articles within days or weeks of their publication. Making use of these tools, Marshall began to mentally assimilate a large body of research relative to the biochemistry of sarcoidosis and other inflammatory diseases.
His search for answers within simply the biochemistry of the disease led to a conviction that there had to be a bacterial pathogenesis. Then in 2001, Marshall read the report of Bachelez and his colleague’s successful use of tetracyclines in treating not only cutaneous sarcoid lesions, but pulmonary and thoracic manifestations as well.
Using the Internet, he was able to contact other researchers to clarify any questions raised by their writings and to share his own discoveries and writings. He was then able to apply his growing knowledge to develop a more detailed pathogenesis for the idiopathic Th1 inflammatory diseases. That in turn led to his detailed treatment relying on a combination of synergistic, low-dose, pulsed antibiotics and concurrent higher-than-usual dosing of an ARB.
Marshall was quick to adopt the emerging field of genomics as his preferred tool in understanding what was causing the Th1 inflammatory processes. Using his advanced computing knowledge, he was able to assemble a powerful simulation environment, quickly identify the antibiotics that were most effective against the bacterial 70S ribosome, and screen all combinations of available statins and sartans to identify the most useful Vitamin D Receptor agonists.
He was also able to make several breakthroughs in the understanding of how corticosteroids worked, and how the secosteroid, Vitamin D, acts to suppress the innate immune system. In March 2006, he was invited to give a "Visiting Professor" presentation to the United States Federal Drug Administration’s Center for Drug Evaluation and Review, describing these genomic breakthroughs.
Dr. Marshall is currently a Director of the Autoimmunity Research Foundation, Thousand Oaks, California. He has recently been appointed Adjunct Professor in the School of Biological Sciences and Biotechnology at Murdoch University.
Dr. Marhall's published papers, FDA applications and scientific presentations may be seen here.
You will find summary biographies of Dr. Marshall and the other Autoimmunity Board members, on the Autoimmunity Research Foundation's web site at URL
http://AutoimmunityResearch.org/about.htm
It was my studies of DM types 1 and 2 at SCGH (Perth) and Hospital for Sick Children (Toronto) that started me off on this oddyssey, nearly 30 years ago. Here is a link to my UWA thesis, FYI...
and a couple early papers:
Treatment of cryptorchidism with pulsatile luteinizing hormone-releasing hormone (LH-RH)
New microprocessor-based insulin controller.
Working with terminally ill Diabetics showed me the essential unity of symptoms in autoimmune disease, and my early research showed me how much more complex the disease processes had to be, by comparison with the common dogma at that time. It took me 30 years to unravel that complexity
..Trevor..
____________________
Nothing contained in this site is or should be considered, or used as a substitute for, medical advice, diagnosis or treatment by your physician.
|
Current time is 13:10 | |
|
|
|
|
